RT Journal Article
SR Electronic
T1 FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third Line Treatment of Metastatic Triple-negative Breast Cancer (mTNBC)
JF Clinical Cancer Research
JO Clin Cancer Res
FD American Association for Cancer Research
SP clincanres.3119.2020
DO 10.1158/1078-0432.CCR-20-3119
A1 Wahby, Sakar
A1 Fashoyin-Aje, Lola
A1 Osgood, Christy L.
A1 Cheng, Joyce
A1 Fiero, Mallorie H.
A1 Zhang, Lijun
A1 Tang, Shenghui
A1 Hamed, Salaheldin S
A1 Song, Pengfei
A1 Charlab, Rosane
A1 Dorff, Sarah E.
A1 Ricks, Tiffany K.
A1 Barnett-Ringgold, Kimberly
A1 Dinin, Jeannette
A1 Goldberg, Kirsten B.
A1 Theoret, Marc R.
A1 Pazdur, Richard
A1 Amiri-Kordestani, Laleh
A1 Beaver, Julia A
YR 2020
UL http://clincancerres.aacrjournals.org/content/early/2020/11/07/1078-0432.CCR-20-3119.abstract
AB On April 22, 2020, the FDA granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY; Immunomedics, Inc.) for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Approval was based on data from the IMMU-132-01 trial, a single-arm, multicohort, multicenter, Phase 1/2 trial of sacituzumab govitecan. The assessment of efficacy was based on 108 patients with mTNBC who had previously received at least two prior lines of therapy in the metastatic setting and who received sacituzumab govitecan 10 mg/kg intravenously (IV). The assessment of safety was based on 408 patients with advanced solid tumors who had received sacituzumab govitecan at doses up to 10 mg/kg IV. The primary efficacy endpoint was investigator-assessed objective response rate (ORR) and duration of response (DoR) was a key secondary endpoint. The ORR was 33.3% [36/108, 95% CI: 24.6, 43.1], and median DoR among responders was 7.7 months (95% CI: 4.9, 10.8). The most common adverse reactions occurring in ≥25% of patients were nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, rash, decreased appetite, and abdominal pain. This article summarizes the FDA review process and data supporting the approval of sacituzumab govitecan.